Yeast as a Model for Studies on Aβ Aggregation Toxicity in Alzheimer’s Disease, Autophagic Responses, and Drug Screening

Part of the Methods in Molecular Biology book series (MIMB, volume 1303)

Abstract

The Aβ peptide is widely considered a major cause of Alzheimer’s disease since it causes neuronal death in an oligomerisation-dependent manner. In order to identify new inhibitors of Aβ that may be chemo preventative for Alzheimer’s disease, a yeast assay that qualitatively determines the amounts and state of the human Aβ42 peptide has been developed. Yeast assays such as this can be applied to studies on aggregation toxicity, autophagic responses and drug screening in Alzheimer’s disease.

Key words

Alzheimer’s disease Amyloid beta Autophagy Bioassays Flow cytometry Oligomerisation Protein aggregation Protein misfolding Yeast 

References

  1. 1.
    Wurth C, Guimard NK, Hecht MH (2002) Mutations that reduce aggregation of the Alzheimer’s Aβ42 peptide: an unbiased search for the sequence determinants of Aβ amyloidogenesis. J Mol Biol 319:1279–1290PubMedCrossRefGoogle Scholar
  2. 2.
    Kim W, Kim Y, Min J et al (2006) A high-throughput screen for compounds that inhibit aggregation of the Alzheimer’s peptide. ACS Chem Biol 1:461–469PubMedCrossRefGoogle Scholar
  3. 3.
    Porzoor A, Macreadie I (2013) Application of yeast to study the tau and amyloid-beta abnormalities of Alzheimer’s disease. J Alzheimers Dis 35:217–235PubMedGoogle Scholar
  4. 4.
    Caine J, Sankovich S, Antony H et al (2007) Alzheimer’s Aβ fused to green fluorescent protein induces growth stress and a heat shock response. FEMS Yeast Res 7:1230–1236PubMedCrossRefGoogle Scholar
  5. 5.
    Macreadie I, Lotfi-Miri M, Mohotti S et al (2008) Validation of folate in a convenient yeast assay suited for identification of inhibitors of Alzheimer’s Aβ aggregation. J Alzheimers Dis 15:391–396PubMedGoogle Scholar
  6. 6.
    Amberg DC, Burke D, Strathern JN (2005) Laboratory CSH. Methods in yeast genetics: a Cold Spring Harbor laboratory course manual. CSHL Press, New YorkGoogle Scholar
  7. 7.
    Douaud G, Refsum H, de Jager CA et al (2013) Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110:9523–9528PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Wolozin B, Wang SW, Li NC et al (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med 5:20PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Macreadie IG, Johnson G, Schlosser T et al (2006) Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 262:9–13PubMedCrossRefGoogle Scholar
  10. 10.
    Mumberg D, Mailer R, Funk M (1995) Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene 156:119–122PubMedCrossRefGoogle Scholar
  11. 11.
    Bharadwaj PR, Verdile G, Barr RK et al (2012) Latrepirdine (Dimebon™) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast. J Alzheimers Dis 32:949–967PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.School of Applied Sciences and Health Innovations Research InstituteRMIT UniversityMelbourneAustralia

Personalised recommendations